Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 8/20 | 0.49 |
| ▸ | JAK1 | P23458 | 8/20 | 0.49 |
| ▸ | TYK2 | P29597 | 8/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.49 |
| ▸ | KIT | P10721 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30843217 | 1.00 | BCAT2 (0.67) | BCAT2POLBGAAPLK1JAK2 | |
| SCHEMBL4805233 | 0.85 | POLB (0.58) | BCAT2POLBGAAPLK1LMNA | |
| SCHEMBL19071638 | 0.84 | POLB (0.54) | BCAT2POLBGAAPLK1JAK2 | |
| SCHEMBL11435059 | 0.83 | POLB (0.56) | BCAT2POLBGAAPLK1LMNA | |
| SCHEMBL1127863 | 0.83 | CA1 (0.71) | BCAT2POLBGAALMNAPABPC1 | |
| SCHEMBL10435055 | 0.83 | CA2 (0.71) | BCAT2POLBGAAPLK1CA1 | |
| SCHEMBL31650197 | 0.83 | POLB (0.56) | BCAT2POLBGAAPLK1LMNA | |
| SCHEMBL11435058 | 0.81 | POLB (0.55) | BCAT2POLBGAAPLK1LMNA | |
| SCHEMBL7974285 | 0.81 | POLB (0.55) | BCAT2POLBGAAPLK1JAK2 | |
| SCHEMBL2451515 | 0.80 | BCAT2 (0.61) | BCAT2POLBGAALMNAPABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056862-B2 | Thioxothiazolidine derivative having Ras function inhibitory effect | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2015-06-16 | — | — | US | disclosed |
| US-9056862-B2 | Thioxothiazolidine derivative having Ras function inhibitory effect | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2015-06-16 | — | — | US | disclosed |
| US-20140194412-A1 | THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT | KNC LABORATORIES CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20140194412-A1 | THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT | KNC LABORATORIES CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
| EP-1835340-A1 | Positive resist composition and pattern formation method using the positive resist composition | FUJIFILM Corporation (JP) | 2007-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | BCAT2 2486/4885POLB 2414/4885GAA 1904/4885 |
| US-20140194412-A1 | THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT | KRAS, NRAS, RASSF5 | BCAT2 2088/4885POLB 4545/4885GAA 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.